HSD3B2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL734885	1.00	1/20
SCHEMBL955866	1.00	1/20
SCHEMBL955869	1.00	1/20
SCHEMBL956891	1.00	1/20
SCHEMBL956892	1.00	1/20
SCHEMBL960361	1.00	1/20
SCHEMBL955691	0.90	1/20
SCHEMBL955692	0.90	1/20
SCHEMBL959645	0.90	1/20
SCHEMBL959647	0.90	1/20
SCHEMBL955579	0.86	1/20
SCHEMBL955581	0.86	1/20
SCHEMBL960764	0.85	1/20
SCHEMBL960766	0.85	1/20
SCHEMBL956118	0.84	1/20
SCHEMBL956119	0.84	1/20
SCHEMBL957664	0.84	1/20
SCHEMBL957665	0.84	1/20
SCHEMBL736571	0.84	1/20
SCHEMBL956805	0.84	1/20

Clinical trials — most relevant to HSD3B2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment	PHASE4	RECRUITING
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study	PHASE3	UNKNOWN
The Role of Mineralocorticoid Receptors in Vascular Function	PHASE2/PHASE3	COMPLETED
Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia	PHASE3	COMPLETED
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia	PHASE1/PHASE2	COMPLETED
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer	PHASE2	COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia	PHASE2	WITHDRAWN
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia	PHASE2	COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency	PHASE1	COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency	nan	UNKNOWN
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas	nan	UNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Linear Growth of Children With Congenital Adrenal Hyperplasia	nan	UNKNOWN
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension	nan	UNKNOWN
Fertility and Pregnancy in Patients With Classic Congenital Adrenal Hyperplasia	nan	COMPLETED
Final Height in Patients With CAH	nan	UNKNOWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers	nan	UNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency	nan	COMPLETED
Adrenal Function in GHD Children	nan	COMPLETED
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	nan	RECRUITING
Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)	nan	COMPLETED
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes	nan	NOT_YET_RECRUITING
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.	nan	UNKNOWN
Impact of 11-oxygenated Androgens on Metabolic Dysfunction of Women With Polycystic Ovary Syndrome	nan	UNKNOWN
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH	nan	COMPLETED
Novel Biomarker for Development of T2D	nan	COMPLETED
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HSD3B2 binder may also engage these)

Protein	Name	Similarity
Q64421	—	1.000	Q64421 →
P27365	—	1.000	P27365 →
HSD3B1	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	1.000	landscape →
P24815	—	0.999	P24815 →
Q60555	—	0.999	Q60555 →
P22071	—	0.998	P22071 →
P26150	—	0.998	P26150 →
O35469	—	0.996	O35469 →
Q62878	—	0.995	Q62878 →
O46516	—	0.995	O46516 →
P22072	—	0.995	P22072 →
P14893	—	0.995	P14893 →
Q9N119	—	0.995	Q9N119 →
O35296	—	0.993	O35296 →
P26149	—	0.993	P26149 →
P27364	—	0.992	P27364 →
Q5IFP1	—	0.991	Q5IFP1 →
Q61767	—	0.990	Q61767 →
Q61694	—	0.986	Q61694 →
Q5PPL3	—	0.983	Q5PPL3 →
Q4R7R1	—	0.983	Q4R7R1 →
Q9D665	—	0.982	Q9D665 →
Q9R1J0	—	0.980	Q9R1J0 →
Q15738	—	0.979	Q15738 →
A8DZE7	—	0.978	A8DZE7 →
Q8WUS8	—	0.977	Q8WUS8 →
Q32L94	—	0.972	Q32L94 →
Q62904	—	0.971	Q62904 →
Q3ZBE9	—	0.970	Q3ZBE9 →
HSD17B7	3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7	0.969	landscape →